AIFF

Commercial Agreement Announcement: Firefly Neuroscience, Inc. has entered into a commercial agreement with the Institute of Human Genetics at Heidelberg University Hospital to utilize its FDA-cleared Brain Network Analytics platform for neuroscience research, focusing on analyzing Electroencephalograms data until 2026.

Research Goals: The collaboration aims to combine clinical expertise and proprietary technology to gain insights into the brain's functional architecture in rare genetic conditions, ultimately enhancing the understanding and treatment of cognitive disorders.

Collaboration on Genetic Research: Firefly Neuroscience is collaborating with Prof. Dr. Christian Schaaf from Heidelberg University Hospital on a study investigating the neurophysiological effects of 15q13.3 copy number variants (CNVs) using EEG technology, aiming to identify biomarkers and support diagnostic strategies for neurodevelopmental disorders.

Commercial Strategy and Technology Development: Firefly is focusing on building its licensing business as part of its commercial strategy, leveraging its FDA-cleared Brain Network Analytics technology to enhance brain health outcomes and attract pharmaceutical companies for drug research and clinical trials.

Research Findings: A study shows that combining EEG/ERP and volumetric MRI (vMRI) can accurately differentiate between subjective cognitive decline, mild cognitive impairment, and dementia with an accuracy of about 87%, enhancing early detection and treatment opportunities.

Firefly's Advancements: Firefly Neuroscience's acquisition of Evoke Neuroscience has provided access to a large EEG dataset, supporting the development of AI-driven solutions aimed at improving brain health outcomes for neurological and mental disorders.